Genentech

2024 top biotech and pharma employers survey by Science magazine identifies leading companies in the industry

Vabysmo PFS is reportedly the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal…

Climate change-related exacerbations of MS will necessitate the development of more effective DMTs as disease flare ups become…

The priority review is granted for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Half of the trial participants had developed T cells that can potentially recognise cancerous cells and stop them from re-emerging

Every year, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS) in the US, and there remains a high…

Approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional…

Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations

The approval is primarily based on the results of two Phase III studies, VIALE-A and VIALE-C

The drug is used to treat metastatic RET fusion-positive non-small cell lung cancer